Share Name Share Symbol Market Type Share ISIN Share Description
Smith & Nephew Plc LSE:SN. London Ordinary Share GB0009223206 ORD USD0.20
  Price Change % Change Share Price Shares Traded Last Trade
  11.00 0.71% 1,551.00 3,108,935 16:35:24
Bid Price Offer Price High Price Low Price Open Price
1,554.00 1,555.50 1,555.50 1,537.50 1,538.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 3,335.27 179.93 37.52 42.1 13,582
Last Trade Time Trade Type Trade Size Trade Price Currency
17:34:57 O 1,938,352 1,548.00 GBX

Smith & Nephew (SN.) Latest News

More Smith & Nephew News
Smith & Nephew Investors    Smith & Nephew Takeover Rumours
Smart Money!
SN. is a large holding in the following funds:
 Fund  Percentage of Fund  Last Updated 

Smith & Nephew (SN.) Discussions and Chat

Smith & Nephew Forums and Chat

Date Time Title Posts
09/6/202114:43*** Smith and Nephew ***409
10/1/201113:03Smith and Nephew 200867
09/1/201117:12Smiths: Charts and News etc.296
25/9/200615:09Smith&Nep. Why the rise?75

Add a New Thread

Smith & Nephew (SN.) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Smith & Nephew trades in real-time

Smith & Nephew (SN.) Top Chat Posts

Smith & Nephew Daily Update: Smith & Nephew Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker SN.. The last closing price for Smith & Nephew was 1,540p.
Smith & Nephew Plc has a 4 week average price of 1,460.50p and a 12 week average price of 1,357.50p.
The 1 year high share price is 1,681.50p while the 1 year low share price is currently 1,317p.
There are currently 875,694,866 shares in issue and the average daily traded volume is 3,141,225 shares. The market capitalisation of Smith & Nephew Plc is £13,582,027,371.66.
1nf3rn0: Credit Suisse upgraded shares of artificial hip and knee maker Smith & Nephew on Wednesday to 'outperform' from 'neutral', lifting the price target to 1,805p from 1,560p as it pointed to "underappreciated growth drivers".The bank argued that S&N is an underappreciated elective surgery recovery play in the near term and that investors underestimate the combined power of recently-acquired growth drivers with corresponding return leverage mid-term.It upped its FY21-23 sales/adjusted earnings per share estimates by an average 2%/6%, leaving it 3%/5% above Bloomberg consensus."As the drivers become clearer gaining the confidence of investors, we expect Smith & Nephew stock to reverse its material underperformance over the past 12 months," Credit Suisse said.The bank noted that since late 2017, Smith & Nephew has bought several bolt-on technologies, committing close to $1.6bn, and with associated negative M&A effects on trading margin of around 150 basis points for FY21."We deep-dived into the potential for the new technologies," it said. "We believe the Wound Biologics/Sports Medicine/Extremities/ENT franchises can add circa 80/15/40/40bps to group underlying growth mid-term."This would turn Smith & Nephew from low-to-mid single digit into mid-to-high single digit underlying growth mode and generate relevant operating leverage, providing upside to trading margin."
essentialinvestor: Terry holds Stryker, from memory. Not SN as far as I'm aware.
hubshank: Very encouraging trading statement. May well see that target price of £19.85 before too long...
philanderer: Berenberg reiterates buy with a target price of 1,985.0p
its the oxman: Added as well. Poor sentiment and expected newsflow very much in the price. Any slight expectation of a pick up or bid and we could be 20% higher quite quickly. Hopefully the downside is limited.
gclark: I see it on a forward forecast PE for 2021 of 10, at a share price of £14, which is not steep. xxx:// It seems like a decent source of information but we are all limited by our information source!
suetballs: 4 brokers cut tp this am. Lowest £14.23 highest £19.85. Berenberg the highest still has sn. as a buy. Suet
suetballs: Yep - post Brexit and covid I am expecting a mini boom for the ftse. sn.'s prospects look very encouraging. Suet
gclark: Well it is difficult to understand this continued drop as the prospects seem good in the near future - with us coming out of lockdown gradually and a much bigger emphasis on elective surgeries which have been delayed. All I can think now is that a large institution is selling, perhaps for other reasons than their view on SN.? Or may be, somebody in their company doesn't like the future prospects of SN. But I beg to differ with them - we shall see who is right!
its the oxman: Share price certainly not easing the pain of covid lockdowns. Best hope for the short term seems to be a bid from as whole uk market remains cheap.
Smith & Nephew share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Smith & Ne..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210622 20:50:08